I agree with you Bart. The only big problem is that the world at large seems unaware of OvaDx to reach the same conclusion that Ovadx is a far superior test. Arrayit needs to get the word out in a similar fashion outlining the results of their clinical studies and have the medical community compare and contrast the products. If Arrayit can do this before the Cancer conference on June 6, when these doctors make their presentation, OvaDx should be brought up for discussion for doctors to learn about it.
Market Data 
Markets 
AI
